Menu
GeneBe

AMFR

autocrine motility factor receptor, the group of Ring finger proteins

Basic information

Region (hg38): 16:56361451-56425545

Links

ENSG00000159461NCBI:267OMIM:603243HGNC:463Uniprot:Q9UKV5AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • spastic paraplegia 89, autosomal recessive (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Spastic paraplegia 89, autosomal recessiveARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic37119330

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the AMFR gene.

  • Inborn genetic diseases (19 variants)
  • Marfanoid habitus and intellectual disability (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the AMFR gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
0
missense
18
clinvar
2
clinvar
20
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
0
Total 0 0 18 2 0

Variants in AMFR

This is a list of pathogenic ClinVar variants found in the AMFR region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-56362995-C-A not specified Uncertain significance (Jul 09, 2021)2236149
16-56363024-G-A not specified Uncertain significance (Feb 26, 2024)3115539
16-56363055-G-A Breast ductal adenocarcinoma Uncertain significance (Jul 20, 2015)221329
16-56364051-C-T not specified Likely benign (Feb 07, 2023)2481533
16-56364099-G-A not specified Uncertain significance (Jul 13, 2022)2301442
16-56367527-G-A not specified Uncertain significance (Nov 17, 2022)2371564
16-56369318-T-A not specified Uncertain significance (Feb 15, 2023)2485278
16-56385543-GGTGCAGTGAGCCAAGATCGCACCACTGCACTCTAAGCCTGGGCAATGAAGGAAGACCCTGCCTCCAGAAAAAAAAATTTTTTTTTTTTTTGGCTAAAATCGAAGGAGTCCCAAGGTAGGCCTAGATCACAACAGAGTGAACCTAGTAGTGTTCAGAAAAGGTTAGATTATCCGCCACAGAAATAAAATGAACGTTTCAAAATTTAAAACACAGGAATGTAAATGGTCCCAGTAAATAAAAAGAAGCCCCTAAAAATCCTTCCACTCTGCCAGAGCAGAGTAAGACCAACAAGGTCATATACCCGGCACACACGCTCTAGCTGTTCTTTCCCTCCTAATTCCCAGTGATCTTCTTAAAGCAGCTAGCAGACCTTACCATTGCATTGAGCTGGGAGTTGCTGGCCTGCGTAATGCCAAGAATGTTGGTGGTGTGCATCACTTCAACCGAAAAACTCGGCAGCCAGCTCGCAATCCGAGACCCTGAAACAAACAAGAATCCAGTGTAAGTTTCAGAGCCCTGACTCTTTCCCCCGTCATCTGCTCTCACGGTAGCCACTGTAATGGCTGGTGTTCACTGAGGGCTTCTTGTATGGCAGGCTTCTCATGCCAAGTGTTTCACGTGGACTAGCTCATTTAATCCTCACTACACTCCACATGGTACCTCCTATTATCATTCTTATAGTATCCTTCTCAAAGATATAGCACTAGTACCCTTGGTCTTTGGTCTCTGAGGCACTTAGAAGTTAGGGGACTTGTCCAAGATCACACAGTTTAACTATGATGGCCAAGATGTGAAGCCAGACAGGCAAGCTCTAGAACCCTTCACTGCTGAGCAATCCTGCTTTCCAGGGGGGCTGGATGCAGCCCAGCCCAGCGCCCTCACACGCTCAGCCTGGGAGATGAGGAAGCTTTTCAAGGCTCTAAAGCTTCTACAACACATGAGCTTTGGCTCCTCTTTCACAAGCTACACAAATGACTACTCACTTGGAGGCATTTTCACATTTACTTTTAGGAAGTATTTTTTCTTTAATCTTAAAAGCCGTGGTTTTCTGATTCAAAATTCTTTTTAAATTGTTCTATTCTACAAAAAGGCTTGTAGACTAACAGCACCAAGAAGTCTGCTGCTTCTGTTATTTCCCGAAGAAAACAGGAGCCTAAGATACAACAGCACCAAGAATTGGCTGTAAAACAACCCAATTATCAAGCTACACATTTAAGGCTGCTTTTCATTCCTTCACAAAGAAACACTGATGCATGGAACAGAAAATCAAGTGTGGCCAGGAGCAGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCTAAGGCGGGCAGATCACAAGGTCAGGAGATCAAGACCATCTTAGCCAAAATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCAGGCATGGGGGCACGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCACTTGAACCAGGGAATCAGCGGTTGCATTGAGTTGAGATCACGCCACCGCACTCCAGCCTGGCAACAGGGCAAGACTCCATCTCAAAAAAAAAAAAAAAATCAAGTGGAATGGCTATCTCAAAGGTCTTGAGATGGGTACAAACAAAACGTACCCATTTAAGAAATGGATACTTATTTCATGTACTAACTAGGGAGAAATAAAGTTGACTTTATCTATTTTGACTAAATTTTTAGTAGTCATAATTCACAAAATAATGGATTACATAGCCAGGTCTCATCTCTAATATTGCTAGTATATTTCAGAAGTTTTACCTGGAAGAGCCCTTCATTCACAGCCACCAAACCAGGTCCTCTAAACCCCTCTAGCATTCTGGGCCCAGCCAGCCAAGTAGCCCCACCTACTCTTCTGGGAGACATGACTCTACTCCCCCTAGTCCCTTCTTTGAGGGATTTCACCAACACGACACCATCCCCACTGTACTCCATTCTTGAAACTCAAATCAGGGATGCGAATAGCACTACTGCTAACAAAATTCCAGGGATGCTTGTGTTACAGTAATAATTATAAACATGAACTCACAGAATTTAGCAGTACTGGACTGTTGAAAATCAACAGCAGCTTAATGTGAATTAAGGAAGGATGATCAACCAGACCTTGATATGTCATAGCCTTAGAATTTTAAGTGTGGTTTTCATTACAACTCCTTTTAACACTGCCGGGAGGCAGAACATTTATATTTTATGGACAAAGCAACAGGGTTCCAGCTCTGATTCTGCTTCTGGTACTCACCAGAAAGGCTTCTCAATGATCCTTCATTATATGCTTAAATGCTACACAAATGCAATATATTATTAGCAAAGGTTAACTATTGAGCTAATTAAGTGTGCTCCTTGAAGGCATGGTTGATTCAGTTTTACTCCTCCACCCTCCTGCCCCACCCTGCCCATATTGACATGGAATCAGGCAAAATGCCTGGAACCCCTCTGTTTGTTCTATCTCTATCCATCCATCCATCCATCCCACCTAAACACTTTCAATTAAAATTGAAATACAGTCAATGCGTAGCTTAACAACAGGGACACATTCTGAGAAATGTGTTGTTAGGTGATTTCATTGTTGTGCGAACATCATAGAGTATATTTACATAAACCTAAATGGTATAGCTTACTACACACCTAGGCTATACGATATAGTCTATTGTTCTAGGCTACAATCCTGTACAGCATGTTACTATACTGAATGCTGTAGAGGCAATTATAACACAGTGCTAAGTATTTGTGTATCTAAACATATCTAACAGAAAACATACAGTAAAAATATGGTACACAAAAAGTACACCTGCATAGGGCACTTACCAGGAATGAAGCTTGCATGATTAAGGCTGCTCTGGGTGAGTCAGTGAGTGGTGAAATGTGAAGGCCTAGGACATTACTGTGAACTCCTGCAGACTTTATAAACACTGTACACTTAGGCTACACTAAATTCATGACAAAATGTTTCTTTCTATATTCAATAAATTAAATTTAGCTTACTATAAGTTTTTTACTTCATAATCTTAATTTTTTTAACTTTTTGACTCTTGTAGTAACACTTAGCTTAAAATTCAAACACCCTGTACAGCTGTCGAAAATATTTTCTTTTTTATTCTATAAGAGTTTTTCTATTTCTAAAAGTTTTAATTTTACTTTTTAAATTTTTTTGGCTAAAAACTAAGATACAAACACACGCATTAGCCTAAGCCTACACAGGTCAGGAGCATCAGTATCACTGTCGACCACCTCCACCTCCTGTCCCACTGGAACGTCTTCAGGGGCAGTAACACGCATGGAGCTGTCATCTCCTAGAATAACAATACCTTATTTTGGAATACCTCCTGAAGGACCTGCCTGAGGCTGCTTTACAGTAAATTTTTTTTGTATGTAAGTATGAGTACACTTTAAAATAATGATAAAAACTGTAGTAAATACCAGACTACAGGAATTTTTTAGGTCCATTATCATCTTATGGGACCACTGCCATATATATGGTTTGCCATGGAGTGAAATGTCGTTATGGGGCACATGACTGTATAATATTAAACTGGTCTATACAGGGCAATTTATAACTAAAATAGTATCTGCTTAAGGGAGAACACCCCTTAGGTATAGTTTCAGAGGTTGAAACCAACTAACCATCGAAATGGAAGAAGTGATTGTGTTGGTTTAAGCGAGGTCTCCCTTCGGCTGCTGCTACAGGAACCAAATTCTCATCCAAGTTCTCTCCTTGATGTTCTTCCCTGACACGATTATTGTCGGCAATATTAAGAGACATTCTGCATGTTGGACAGGAGGTGTCTTGTTCTAGCCAGGAACGAAGACAGGAGCTACCAAAAAGTCCAAAAGAAGATACGTCAGCATCCTTGATTGTTCCTTAGCATACTTTGTGAGAATTCACCCAGAAGTACTCTGGATATATCAAAT-G Spastic paraplegia 89, autosomal recessive Pathogenic (May 25, 2023)2502912
16-56385954-T-A not specified Uncertain significance (Dec 18, 2023)3115512
16-56385954-T-C not specified Uncertain significance (Mar 29, 2022)2399009
16-56389220-C-T not specified Uncertain significance (Feb 15, 2023)2456083
16-56389242-C-G not specified Uncertain significance (Dec 06, 2023)3115506
16-56389295-C-T Marfanoid habitus and intellectual disability Uncertain significance (-)689680
16-56389296-G-A not specified Uncertain significance (Jan 23, 2024)3115503
16-56389308-C-T not specified Uncertain significance (Feb 28, 2024)3115497
16-56389364-C-T not specified Uncertain significance (Jun 12, 2023)2559643
16-56401760-T-G not specified Uncertain significance (Dec 03, 2021)2264289
16-56401818-G-T not specified Uncertain significance (Dec 16, 2023)3115487
16-56401840-A-C not specified Uncertain significance (Sep 16, 2021)2384517
16-56403019-T-C not specified Uncertain significance (Sep 20, 2023)3115593
16-56403030-C-T not specified Uncertain significance (Oct 26, 2021)2211998
16-56403040-G-A not specified Uncertain significance (Dec 27, 2023)3115582
16-56403082-C-T not specified Uncertain significance (May 04, 2023)2543779
16-56403084-A-AGGCT Spastic paraplegia 89, autosomal recessive Pathogenic (May 25, 2023)2502911
16-56404928-A-G not specified Uncertain significance (Dec 21, 2022)2365559

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
AMFRprotein_codingprotein_codingENST00000290649 1464087
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.00005841.001257110371257480.000147
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.872673680.7260.00002294205
Missense in Polyphen5087.1820.57351881
Synonymous1.301181370.8590.000008941284
Loss of Function3.201332.80.3960.00000183354

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001520.000152
Ashkenazi Jewish0.000.00
East Asian0.0001630.000163
Finnish0.0008320.000832
European (Non-Finnish)0.0001060.000105
Middle Eastern0.0001630.000163
South Asian0.00003710.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: E3 ubiquitin-protein ligase that mediates the polyubiquitination of a number of proteins such as CD3D, CYP3A4, CFTR and APOB for proteasomal degradation. Component of a VCP/p97- AMFR/gp78 complex that participates in the final step of endoplasmic reticulum-associated degradation (ERAD). The VCP/p97- AMFR/gp78 complex is involved in the sterol-accelerated ERAD degradation of HMGCR through binding to the HMGCR-INSIG complex at the ER membrane and initiating ubiquitination of HMGCR. The ubiquitinated HMGCR is then released from the ER by the complex into the cytosol for subsequent destruction. Also regulates ERAD through the ubiquitination of UBL4A a component of the BAG6/BAT3 complex. Also acts as a scaffold protein to assemble a complex that couples ubiquitination, retranslocation and deglycosylation. Mediates tumor invasion and metastasis as a receptor for the GPI/autocrine motility factor. {ECO:0000269|PubMed:10456327, ECO:0000269|PubMed:11724934, ECO:0000269|PubMed:16168377, ECO:0000269|PubMed:19103148, ECO:0000269|PubMed:24424410}.;
Pathway
Protein processing in endoplasmic reticulum - Homo sapiens (human);Sterol Regulatory Element-Binding Proteins (SREBP) signalling;ER Quality Control Compartment (ERQC);Calnexin/calreticulin cycle;Post-translational protein modification;Metabolism of proteins;Asparagine N-linked glycosylation;N-glycan trimming in the ER and Calnexin/Calreticulin cycle (Consensus)

Recessive Scores

pRec
0.172

Intolerance Scores

loftool
0.602
rvis_EVS
-1.09
rvis_percentile_EVS
7.05

Haploinsufficiency Scores

pHI
0.317
hipred
Y
hipred_score
0.652
ghis
0.609

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
S
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.876

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Amfr
Phenotype
liver/biliary system phenotype; neoplasm; immune system phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;

Gene ontology

Biological process
protein polyubiquitination;protein folding;ubiquitin-dependent protein catabolic process;signal transduction;aging;learning or memory;ubiquitin-dependent ERAD pathway;endoplasmic reticulum unfolded protein response;positive regulation of protein binding;protein complex oligomerization;protein autoubiquitination;protein K48-linked ubiquitination;endoplasmic reticulum mannose trimming
Cellular component
nucleus;endoplasmic reticulum;endoplasmic reticulum membrane;Golgi apparatus;membrane;integral component of membrane;integral component of endoplasmic reticulum membrane;dendrite;growth cone;protein-containing complex;Derlin-1 retrotranslocation complex;neuronal cell body;endoplasmic reticulum quality control compartment;perinuclear region of cytoplasm
Molecular function
ubiquitin-protein transferase activity;protein binding;protein binding, bridging;ubiquitin-ubiquitin ligase activity;signaling receptor activity;identical protein binding;metal ion binding;chaperone binding;ubiquitin protein ligase activity;BAT3 complex binding;ubiquitin-specific protease binding